Giving patients with a common form of breast cancer an immunotherapy drug before surgery appears to boost outcomes, a n ...

This trial assessed adding an infusion of the drug nivolumab—or a placebo—to the pre-surgery phase and then assessing how ...

For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 ...

A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...

Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.

Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...

The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma ...

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

Adding an immunotherapy drug to the chemotherapy that patients receive ahead of surgery can dramatically improve breast cancer cure rates.